CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-

Go back to CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-
(NASDAQ: CRVO) Delayed: 2.45 +0.01 (0.41%)
Previous Close $2.44    52 Week High
Open $2.49    52 Week Low
Day High $2.61    P/E N/A 
Day Low $2.37    EPS
Volume 132,043